Research programme: galectin inhibitors - GlycoMimetics

Drug Profile

Research programme: galectin inhibitors - GlycoMimetics

Alternative Names: Galectins 1, 3 & 9 antagonists - GlycoMimetics

Latest Information Update: 22 Jun 2016

Price : $50

At a glance

  • Originator GlycoMimetics
  • Class Small molecules
  • Mechanism of Action Galectin 3 inhibitors; Galectin inhibitors; Galectin-1-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Cardiovascular disorders; Fibrosis

Most Recent Events

  • 29 Feb 2016 Early research in Fibrosis in USA (GlycoMimetics 10-K, February 2016)
  • 29 Feb 2016 Early research in Cardiovascular disorders in USA (GlycoMimetics 10-K, February 2016)
  • 29 Feb 2016 Early research in Cancer in USA (GlycoMimetics 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top